Data as of Q4 2025 (Dec 31, 2025)

EcoR1 Capital, LLC

โ€ขCIK: 1587114โ€ขFiling: Q4 2025

**EcoR1 Capital, LLC** manages $2.2B across a concentrated portfolio of 28 positions. The fund exhibits significant conviction in the life sciences sector, with its top holding in ZYME representing $604.8M, accounting for approximately 27.5% of reported assets. Further notable allocations include ANAB at $382.0M and MRX at $290.1M. This structure indicates a deep, high-conviction approach targeting disruptive growth within specialized healthcare markets.

Total AUM
$2.2B
+ $12.2M in options
QoQ Performance
+3.6%
Positions
27
+ 1 option
Top 10 Concentration
85.9%
Latest Filing
Q4 2025

Top Holdings Allocation

ZYME
ANAB
JAZZ
CRNX
ZYME27.9%
ANAB17.6%
JAZZ13.4%
CRNX9.2%
CNTA3.6%
CRSP3.4%
MBX3.1%
IMNM2.8%

๐Ÿ“ˆ Biggest Buys

CNTA
CENTESSA PHARMACEUTICALS PLC
+466.4%
3.6% of portfolio
ZBIO
ZENAS BIOPHARMA INC
NEW
1.3% of portfolio
GPCR
STRUCTURE THERAPEUTICS INC
NEW
1.1% of portfolio
PCVX
VAXCYTE INC
NEW
1.0% of portfolio
VYGR
VOYAGER THERAPEUTICS INC
+497.2%
0.7% of portfolio

๐Ÿ“‰ Biggest Sells

XNCR
XENCOR INC
-47.1%
2.3% of portfolio
IMNM
IMMUNOME INC
-30.0%
2.8% of portfolio
SRZNW
SURROZEN INC
-93.3%
0.0% of portfolio

Sector Breakdown

Other100.0%

๐Ÿšช Exited Positionssold since Q3 2025

QURE
UNIQURE NV
SOLD
$232.8M
TNGX
TANGO THERAPEUTICS INC
SOLD
$89.3M
APLS
APELLIS PHARMACEUTICALS INC
SOLD
$78.0M
MDGL
MADRIGAL PHARMACEUTICALS INC
SOLD
$34.4M
RNAGBP
AVIDITY BIOSCIENCES INC
SOLD
$33.3M
+6 more exited positions

Changes from Q3 2025

NEW9 new positions
โ†‘2 increased
โ†“3 decreased

Historical Filings

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023